X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/02/27/2835852/37216/en/Aclaris-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-a-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/01/16/2809710/37216/en/Aclaris-Therapeutics-Announces-Leadership-Changes-and-Strategic-Business-Review.html
https://www.globenewswire.com//news-release/2024/01/10/2806967/37216/en/Aclaris-Therapeutics-Announces-Top-line-Results-from-4-Week-Phase-2b-Trial-of-ATI-1777-for-Mild-to-Severe-Atopic-Dermatitis.html
https://www.fiercebiotech.com/biotech/aclaris-lays-46-staff-resurrects-zunsemetinib-potential-cancer-treatment
https://endpts.com/aclaris-lays-off-almost-half-its-employees-after-cutting-lead-inflammatory-program/
https://www.globenewswire.com//news-release/2023/12/19/2798883/37216/en/Aclaris-Therapeutics-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2023/12/05/2791335/37216/en/Aclaris-Therapeutics-Announces-Patent-License-Agreement-with-Sun-Pharma-for-Alopecia.html
https://www.globenewswire.com//news-release/2023/11/13/2778890/37216/en/Aclaris-Therapeutics-Announces-Top-line-Results-from-12-Week-Phase-2b-Trial-of-Oral-Zunsemetinib-ATI-450-for-Moderate-to-Severe-Rheumatoid-Arthritis-and-Provides-Corporate-Update.html
https://www.reuters.com/business/healthcare-pharmaceuticals/aclaris-therapeutics-stop-development-rheumatoid-arthritis-drug-2023-11-13/
https://www.globenewswire.com//news-release/2023/11/06/2773930/37216/en/Aclaris-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html
Market Place
Share 
